Is Neurocrine Biosciences (NBIX) A Bargain After Strong Q2 Results And Higher Guidance?

Neurocrine Biosciences (NBIX) reported strong Q2 2026 results and raised full-year INGREZZA sales guidance, yet its share price saw a 10% decline. Despite this dip, the stock has shown positive long-term momentum with significant 90-day and 1-year returns. Simply Wall St's narrative suggests NBIX is undervalued, with a fair value of $192.88 against a current price of $166.80, driven by its diverse CNS pipeline and innovation in biologics.